{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:01:08Z","timestamp":1784930468339,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Anlotinib, a novel multitarget kinase inhibitor of VEGFR, FGFR, PDGFR and c-Kit, has proven to be effective and safe for refractory soft tissue sarcoma patients, but has not been examined in recurrent or metastatic primary malignant bone tumors in a clinical trial setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a multicenter single-arm trial. Patients with pathologically proven recurrent or metastatic primary malignant bone tumors were eligible. Anlotinib was administered orally at 12 mg per day. Each cycle consisted of 2 weeks of treatment followed by 1-week off-treatment. The primary endpoint was progression-free survival (PFS), as assessed in the intention-to-treat (ITT) population. Secondary endpoints included objective response rate (ORR), disease control rate (DCR) and overall survival (OS). Adverse events (AEs) were assessed per NCI CTCAE version 4.03.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 42 patients were enrolled. Median PFS was 5.3 months (95% CI 3.5-8.4 months) in the overall analysis, 4.8 months (95%CI 3.5-7.1 months) in osteosarcoma patients and 2.8 months [95%CI 1.3 months to not reached (NR)] in chondrosarcoma patients. The median OS was 11.4 months (95% CI 10.1 months to NR) in the overall analysis, not reached (95% CI, NR, NR) in osteosarcoma patients and 11.4 months (95% CI 1.8 to 21.1 months) in chondrosarcoma patients. The ORR was 9.52% and DCR was 78.57%. Grade 3 or above AEs occurred in 54.76% of the patients, and included hypertension (19.05%), hypertriglyceridemia (9.52%) and pustulosis\u00a0palmaris et plantaris (7.14%). No treatment-related death was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Anlotinib demonstrated promising antitumor activities in recurrent or metastatic primary malignant bone tumors with manageable AEs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.811687","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:28:03Z","timestamp":1653539283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Lina","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqi","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24121","article-title":"Osteosarcoma Incidence and Survival Rates From 1973 to 2004: Data From the Surveillance, Epidemiology, and End Results Program","volume":"115","author":"Mirabello","year":"2000","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: Current Treatment and a Collaborative Pathway to Success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12885-016-2312-3","article-title":"Gemcitabine and Docetaxel in Relapsed and Unresectable High-Grade Osteosarcoma and Spindle Cell Sarcoma of Bone","volume":"16","author":"Palmerini","year":"2016","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S91217","article-title":"Efficacy and Safety of Ifosfamide-based Chemotherapy for Osteosarcoma: A Meta-Analysis","volume":"9","author":"Fan","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-030-43085-6_2","article-title":"Genomics and the Immune Landscape of Osteosarcoma","volume":"1258","author":"Wu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-Informed Targeted Therapy for Osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","article-title":"Immuno-Genomic Landscape of Osteosarcoma","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing Sarcoma: Current Management and Future Approaches Through Collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100221","article-title":"Advances in Immune Checkpoint Inhibitors for Bone Sarcoma Therapy","volume":"15","author":"Thanindratarn","year":"2019","journal-title":"J Bone Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0017","article-title":"Nccn Guidelines Insights: Bone Cancer, Version 2. 2017","volume":"15","author":"Biermann","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr151","article-title":"A Phase II Trial of Sorafenib in Relapsed and Unresectable High-Grade Osteosarcoma After Failure of Standard Multimodal Therapy: An Italian Sarcoma Group Study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0542","article-title":"Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy: An Open Label Phase Ii Clinical Trial","volume":"24","author":"Xie","year":"2019","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","article-title":"Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development","volume":"11","author":"Shen","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib Inhibits Angiogenesis Via Suppressing the Activation of VEGFR2, Pdgfrbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/847108","article-title":"Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies","volume":"2012","author":"Grande","year":"2012","journal-title":"J Thyroid Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23131","article-title":"A Novel Inhibitor That Targets Multiple Kinases, has Potent Antitumor Activities Against Stem Cell Factor Producing Human Small Cell Lung Cancer H146, Based on Angiogenesis Inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01939.x","article-title":"YN968D1 Is a Novel and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase With Potent Activity In Vitro and In Vivo","volume":"102","author":"Tian","year":"2011","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13536","article-title":"Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.478","article-title":"Anlotinib as a Third-line Therapy in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Multicentre, Randomised Phase II Trial (Alter0302)","volume":"118","author":"Han","year":"2018","journal-title":"Br J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664853","article-title":"Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"Spirit 2013 Statement: Defining Standard Protocol Items for Clinical Trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients With Advanced Refractory Solid Tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00387-9","article-title":"Lenvatinib With Etoposide Plus Ifosfamide in Patients With Refractory or Relapsed Osteosarcoma (ITCC-050): A Multicentre, Open-Label, Multicohort, Phase 1\/2 Study","volume":"22","author":"Gaspar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.5381","article-title":"Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children\u2019s Cancer Group, Pediatric Oncology Group, and Children\u2019s Oncology Group: Learning From the Past to Move Forward","volume":"34","author":"Lagmay","year":"2016","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and Efficacy of Regorafenib in Patients With Advanced Soft Tissue Sarcoma (REGOSARC): A Randomised, Double-Blind, Placebo-controlled, Phase 2 Trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds607","article-title":"Phase II Prospective Study With Sorafenib in Advanced Soft Tissue Sarcomas After Anthracycline-based Therapy","volume":"24","author":"Santoro","year":"2013","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e000798","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib Plus Camrelizumab (Anti-Pd1 Therapy, Shr-1210) for Advanced Osteosarcoma (Apfao) Progressing After Chemotherapy: A Single-arm, Open-Label, Phase 2 Trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.018","article-title":"Programmed Cell Death 1 (Pd-1) Targeting in Patients With Advanced Osteosarcomas: Results From the PEMBROSARC Study","volume":"119","author":"Le Cesne","year":"2019","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11527","article-title":"Single-Agent Expansion Cohort of Lenvatinib (LEN) and Combination Dose-Finding Cohort of LEN + Etoposide (ETP) +Ifosfamide (IFM) in Patients (Pts) Aged 2 to # 25 Years With Relapsed\/refractory Osteosarcoma (Os)","author":"Gaspar","year":"2018","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13726","article-title":"Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib\/II Trial","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and Safety of Regorafenib in Adult Patients With Metastatic Osteosarcoma: A Non-Comparative, Randomised, Double-blind, Placebo-Controlled, Phase 2 Study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.811687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T04:28:06Z","timestamp":1653539286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.811687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":35,"alternative-id":["10.3389\/fonc.2022.811687"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.811687","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"811687"}}